Plasma Derived Therapy Market Size & Share, By Product (Immunoglobulin, Coagulation factors, Albumin, Others), Application (Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, Others), Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Market Outlook:

Plasma Derived Therapy Market exceeded USD 19.34 billion in 2023 and is poised to cross USD 34.91 billion by end of the year 2032, growing at over 6.8% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 19.34 billion
• CAGR (2024-2032): 6.8%
• Forecast Year Value (2032): USD 34.91 billion
• Historical Data Period: 2019-2023
• Largest Region: North America
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

One of the primary growth drivers for the Plasma Derived Therapy Market is the increasing prevalence of chronic and rare diseases that require long-term treatment. Conditions such as hemophilia, immunodeficiencies, and neurological disorders necessitate the use of plasma-derived therapies like clotting factor concentrates and immunoglobulins. As awareness of these diseases grows and more patients are diagnosed, the demand for effective therapies that can manage or improve patient quality of life is also on the rise, thus propelling market growth.

Another significant driver is the advancement in technology and research associated with plasma fractionation processes. Innovations such as improved separation techniques, pathogen suppression technologies, and enhanced purification methods have made it possible to derive high-quality plasma products more efficiently and safely. These technological improvements not only increase the yield of therapeutic products but also enhance their safety profiles, thus driving greater adoption among healthcare providers and patients.

Additionally, the growing investment in the healthcare sector, particularly in developing regions, has further stimulated the Plasma Derived Therapy Market. Governments and private sectors are increasingly allocating funds towards healthcare infrastructure and services, which includes the establishment of plasma donation centers and manufacturing facilities. This investment not only boosts plasma collection and production capabilities but also raises awareness about the importance of plasma therapy, contributing to a larger patient base seeking such treatments.

Report Scope

Report Coverage	Details
Segments Covered	Plasma Derived Therapy Product, Application
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, SA

Industry Restraints:

One of the key restraints impacting the Plasma Derived Therapy Market is the high cost associated with plasma-derived products. The complex processes involved in plasma collection, fractionation, and purification contribute to high production costs, which often translate into elevated prices for end-users. This can limit access to essential therapies, particularly in low- and middle-income countries where healthcare resources may be constrained, thereby affecting overall market growth.

Another critical restraint is the regulatory challenges and stringent guidelines governing the collection and use of human plasma. Regulatory bodies enforce rigorous standards for safety, efficacy, and ethical considerations in plasma therapy, which can lead to lengthy approval processes for new products and therapies. These barriers can slow down innovation and market entry, resulting in a more cautious approach from companies investing in plasma-derived therapies, ultimately impacting the market’s expansion potential.

Regional Forecast:

North America

The Plasma Derived Therapy Market in North America is characterized by a strong demand for various therapies, driven by an increasing prevalence of hemophilia and other bleeding disorders. The U.S. is the largest market, supported by advanced healthcare infrastructure, significant R&D investments, and a high number of plasma donation centers. The growing awareness about plasma-derived therapies and favorable reimbursement policies boost market growth. Canada is also witnessing an increase in the utilization of these therapies, although the market is comparatively smaller. Regulatory support from Health Canada and the focus on expanding plasma collection facilities are expected to enhance market opportunities in the country.

Asia Pacific

The Plasma Derived Therapy Market in the Asia Pacific region is emerging rapidly, with significant growth anticipated in countries such as China, Japan, and South Korea. China is poised for the most substantial growth, driven by rising healthcare expenditures, increasing prevalence of blood disorders, and ongoing regulatory reforms that encourage plasma collection and usage. Japan has a well-established plasma-derived therapy market, supported by a strong healthcare system and innovative treatment options. South Korea is also seeing growth due to rising patient awareness and government initiatives to enhance plasma collection. Overall, the region presents considerable opportunities due to its large population and improving healthcare infrastructure.

Europe

In Europe, the Plasma Derived Therapy Market is well-established, with significant contributions from the United Kingdom, Germany, and France. The United Kingdom is a key player, characterized by stringent regulatory frameworks and robust reimbursement systems that ensure patient access to therapies. Germany stands out with its substantial investments in healthcare R&D and strong plasma donation networks, supporting a growing market for plasma-derived therapies. France is also relevant, with increasing investments in healthcare and efforts to streamline plasma sourcing and processing. The overall European market benefits from strong collaborations between government and private sectors, leading to innovation and improved patient outcomes across the region.

Segmentation Analysis:

In terms of segmentation, the global Plasma Derived Therapy market is analyzed on the basis of Plasma Derived Therapy Product, Application.

Plasma Derived Therapy Market by Product

The Plasma Derived Therapy Market is significantly segmented by product type, which includes Immunoglobulin, Coagulation factors, Albumin, and Others. Immunoglobulin dominates the market, primarily due to its essential role in treating various immunodeficiency disorders and its expanded application in autoimmune diseases. The increasing awareness and diagnosis of primary immunodeficiency diseases are driving the demand for immunoglobulin therapies. Coagulation factors also hold a substantial percentage of the market, being crucial in managing hemophilia and other bleeding disorders. The growth of the coagulation factors segment is propelled by advancements in product efficacy and safety, along with an increase in the prevalence of hemophilia worldwide. Albumin, a vital component for maintaining oncotic pressure and preserving blood volume, is increasingly utilized in hospitals and critical care settings. Its market growth is supported by rising cases of liver diseases and trauma patients. The Others segment, including therapies for diverse conditions, showcases a smaller yet notable share, reflecting ongoing research and development in novel applications of plasma-derived products, potentially driving innovation in this market.

Plasma Derived Therapy Market by Application

In terms of application, the Plasma Derived Therapy Market is primarily segmented into Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, and Others. The Hemophilia segment leads the market due to the increasing prevalence of this genetic disorder, coupled with rising awareness and availability of plasma-derived treatments. The growth of this segment is significantly associated with advancements in treatment methodologies that offer improved patient outcomes and safety profiles. The increasing diagnosis rates of Primary immunodeficiency diseases further bolster the market, as more patients are identified and treated with immunoglobulin therapies. Moreover, the Idiopathic thrombocytopenic purpura segment is gaining traction due to the growing understanding of this condition and the therapeutic role of immunoglobulin in its management. Despite having a smaller share, the Others segment comprises diverse applications for various plasma-derived products, indicating a dynamic approach to treatment options that addresses a broader range of medical conditions, potentially contributing to future market growth as research continues to evolve in this field.

Competitive Landscape:

The competitive landscape in the Plasma Derived Therapy Market is characterized by several key players striving for innovation and market share. The demand for plasma-based therapies has increased significantly due to their effectiveness in treating various conditions, including hemophilia, immune deficiencies, and other chronic disorders. Companies are focusing on strategic collaborations, extensive R&D, and expansion of their product portfolios to improve patient outcomes and address unmet medical needs. The market is marked by a mix of established leaders and emerging firms, with regulatory compliance and quality control remaining critical factors in maintaining competitive advantage. Regional expansions and market penetration strategies are also vital as companies navigate global market dynamics.

Top Market Players

1. Takeda Pharmaceutical Company Limited

2. Grifols S.A.

3. Octapharma AG

4. CSL Behring

5. Baxter International Inc.

6. LFB Group

7. Kedrion S.p.A.

8. Biotest AG

9. Emergent Biosolutions Inc.

10. Buckingham Biotech LLC